Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX) granted a non-qualified stock option inducement to a new employee on October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). The award covers 30,000 shares with an exercise price of $0.97 per share (Nasdaq closing price on the grant date). Options have a 10‑year term and vest over 4 years: 25% on the first anniversary and the remaining 75% in 36 equal monthly installments, subject to continued service. The grant was made outside the company’s 2021 Long‑Term Performance Incentive Plan as permitted by Nasdaq rule as an inducement for employment.

PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase 30,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.

The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date (October 1, 2025) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date ($0.97 per share).

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with Context through the applicable vesting date.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the potential benefits, characteristics, safety and side effect profile of our product candidates, (ii) the likelihood data will support future development of our product candidates, and (iii) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Context Therapeutics
IR@contexttherapeutics.com

FAQ

What did Context Therapeutics (CNTX) announce on October 3, 2025 about employee option grants?

Context announced an inducement grant of 30,000 non‑qualified stock options granted October 1, 2025, at $0.97 per share.

How do the CNTX inducement stock options vest and what is the term?

Options vest over 4 years (25% at year one, then monthly over 36 months) and have a 10‑year term.

Why did Context Therapeutics grant options outside its 2021 plan under Nasdaq rule 5635(c)(4)?

The options were granted as an inducement for a new hire, permitted by Nasdaq Listing Rule 5635(c)(4) when issued outside the 2021 plan.

What exercise price was set for the CNTX inducement options and how was it determined?

The exercise price is $0.97 per share, equal to Context's Nasdaq closing price on the grant date.

Does the press release state any immediate dilution or total outstanding share impact for CNTX from the 30,000 options?

No. The release discloses the 30,000 option award but does not quantify dilution or total outstanding shares.

When was the CNTX inducement grant effective for the employee?

The options were granted to the new employee on their hire date, October 1, 2025.